Stochmal Anna, Czuwara Joanna, Zaremba Michał, Rudnicka Lidia
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Arch Dermatol Res. 2021 Nov;313(9):783-791. doi: 10.1007/s00403-020-02172-0. Epub 2021 Jan 12.
Adiponectin, resistin and leptin belong to adipokines, a group of molecules secreted mainly by the adipose tissue, which impaired expression may be a missing link between various manifestations of systemic sclerosis. Adiponectin, which is also released in small amounts by the endothelium, possesses anti-inflammatory, anti-fibrotic and protective against endothelial injury properties. Both leptin and resistin exhibit features which are contradictory to adiponectin, as they trigger inflammation and the activation of skin fibroblasts. Epoprostenol is a prostaglandin analogue with powerful vasodilator activity and inhibitory effect on platelet aggregation. The aim of the study was to evaluate whether epoprostenol may have an effect on serum adipokine levels in patients with systemic sclerosis.
A total of 27 patients were included in the study and received epoprostenol intravenously (25 µg of per day for 3 consecutive days). Serum concentrations of total adiponectin, resistin and leptin were assessed with enzyme-linked immunosorbent essay (R&D Systems, Minneapolis, MN, USA).
In all SSc patients, the basal level of adiponectin was significantly lower compared to healthy controls (mean 6.00 [Formula: see text] 2.81 μg/ml vs. 8.8 [Formula: see text] 4.3 μg/ml, p = 0.02) and basal level of resistin (mean 11.12 [Formula: see text] 3.36 ng/ml vs. 8.54 [Formula: see text] 3.07 ng/ml p = 0.02) was significantly higher than in the control group. The serum concentration of adiponectin increased significantly after treatment with epoprostenol (6.00 [Formula: see text] 2.81 μg/ml vs 9.29 [Formula: see text] 6.05 μg/ml; P = 0.002). The level of resistin and leptin remained unchanged.
Epoprostenol infusions up-regulate the serum concentration of adiponectin in patients with systemic sclerosis. In our opinion, future studies on treatments in systemic sclerosis should address the issue of their effect on adipokine metabolism.
脂联素、抵抗素和瘦素属于脂肪因子，这是一组主要由脂肪组织分泌的分子，其表达受损可能是系统性硬化症各种表现之间缺失的环节。脂联素也由内皮细胞少量释放，具有抗炎、抗纤维化和保护内皮免受损伤的特性。瘦素和抵抗素均表现出与脂联素相反的特征，因为它们会引发炎症并激活皮肤成纤维细胞。依前列醇是一种具有强大血管舒张活性和抑制血小板聚集作用的前列腺素类似物。本研究的目的是评估依前列醇是否可能对系统性硬化症患者的血清脂肪因子水平产生影响。
共有27例患者纳入本研究，并接受依前列醇静脉注射（每天25μg，连续3天）。采用酶联免疫吸附试验（美国明尼阿波利斯市R&D Systems公司）检测血清中总脂联素、抵抗素和瘦素的浓度。
在所有系统性硬化症患者中，脂联素的基础水平显著低于健康对照组（平均6.00[公式：见正文]2.81μg/ml对8.8[公式：见正文]4.3μg/ml，p = 0.02），抵抗素的基础水平（平均11.12[公式：见正文]3.36ng/ml对8.54[公式：见正文]3.07ng/ml，p = 0.02）显著高于对照组。依前列醇治疗后血清脂联素浓度显著升高（6.00[公式：见正文]2.81μg/ml对9.29[公式：见正文]6.05μg/ml；P = 0.002）。抵抗素和瘦素水平保持不变。
静脉输注依前列醇可上调系统性硬化症患者血清脂联素浓度。我们认为，未来关于系统性硬化症治疗的研究应关注其对脂肪因子代谢的影响问题。
